Psy73 - Economic and Social Burden of Relapsed or Refractory Multiple Myeloma: A Systematic Review of the Literature

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2649
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Arsenic Trioxide-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients: A Meta-Analysis and Systematic Review

OncoTargets and Therapy
OncologyPharmacology
2014English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Systematic Review and Meta-Analysis of the Efficacy and Safety of Novel Monoclonal Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma

Oncotarget
Oncology
2017English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

European Journal of Haematology
MedicineHematology
2007English

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy